Blog
What I saw at DIA RWE 2023
I am just back from Baltimore, Maryland, where I had the joy of attending DIA’s ...
Blog
Advancing RWE in Oncology with Aetion’s CARE Initiative
In late 2022, Aetion announced the launch of the Aetion Coalition to Advance Real‐World ...
Blog
What I saw at ICPE 2023
I just had the pleasure and privilege of attending the 39th International Conference on ...
Blog
Leveraging the SURF screening tool to understand how to identify whether RWE of effectiveness may be acceptable for regulatory decision-making for a clinical development program
Ulka Campbell, Ph.D., is Aetion’s Head of Scientific Strategy. In this role, she uses her ...
Blog
The Inflation Reduction Act Puts Real-World Evidence Front and Center
The drug price negotiation provisions of the Inflation Reduction Act (IRA) will ...
Blog
Implementation of synthetic data generation in the enterprise
By Khaled El Emam | Published: April, 2023 The following article was published by ...
Blog
Aetion submits comments to FDA on recent draft guidance on considerations for externally controlled trials
Earlier this week, Aetion submitted a letter to FDA commenting on the Agency’s recent ...
Blog
Setting Real-World Standards at ISPOR 2023
Aetion joins other industry experts at ISPOR 2023 to discuss standard-setting and ...
Blog
Scientist spotlight: A deeper dive on RCT-DUPLICATE
This week, the final results of the RCT-DUPLICATE (RCT-D) study were published in the ...
Blog
Privacy Assurance FAQ
What is Privacy Assurance? One of the benefits of synthetic data is that it has low ...
Blog
Synthetic Data Generation FAQ
What is synthetic data generation (SDG)? There are many ways to generate synthetic data. ...
Blog
Aetion® Generate FAQ
What is Generate? Aetion® Generate, formerly Replica Synthesis, is Aetion’s scalable ...
Blog
Research spotlight: RWD transferability across borders
Manufacturers are increasingly using real-world data (RWD) to generate real-world ...
Blog
A Solution for Payers to Use Real World Evidence in Pharma Confidently
Tackling three common concerns
Blog
RWE Meaning | Update: What the Omnibus FDA Amendments Mean for RWE
On December 29, 2022, President Biden signed the Consolidated Appropriations Act, 2023, a ...
Blog
Replica Analytics Top 10 Round-up for 2022
By Replica staff
Blog
Validating a Membership Disclosure Metric for Synthetic Health Data
By Lucy Mosquera | Posted On: October 11, 2022 We have just had a paper published in ...
Blog
RWE guidance watch: EUnetHTA’s Direct and Indirect Comparisons guidance
The European Network for Health Technology Assessment (EUnetHTA) recently published two ...
Blog
Aetion’s best practices referenced in ENCePP’s updated Guide on Methodological Standards in Pharmacoepidemiology
On July 1, 2022, the European Network of Centres for Pharmacoepidemiology and ...
Blog
New estimator uses synthetic data generation for more reliable evaluation of re-identification risk in datasets
By Lucy Mosquera and Abhik Das
Blog
Why work at a startup? Because everything you do matters
Several years ago, during a hiring interview for a software engineer position, the ...
Blog
ISPOR Goes Real-World
Regulators, HTAs, and pharma leaders discuss RWE trends with Aetion experts.
Blog
RWE Guidance: NICE’s RWE Framework
This month, the UK’s National Institute for Health and Care Excellence (NICE) released ...
Blog
Utility Metrics for Evaluating Synthetic Data Generation Methods
By Lucy Mosquera and Xi Fang Posted On: April 8, 2022 In order to work with synthetic ...